Profile
Jonathan Michael Poole served as an Independent Director at Codiak BioSciences, Inc. He was a Senior Vice President at Shire Plc from 2006 to 2014.
From 2014 to 2018, he served as the Chief Financial & Accounting Officer at Genocea Biosciences, Inc. He was also an Investment Manager at Avanti Capital PLC and Odyssey Partners Ltd.
In addition, he served as the Head of Strategic Planning & Portfolio Management at Shire Human Genetic Therapies, Inc. From 2018 to 2020, he was the Chief Financial Officer & Treasurer at Evelo Biosciences, Inc. Poole received his undergraduate degree from the University of Durham and his MBA from the London Business School.
Former positions of Jonathan Michael Poole
| Companies | Position | End |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Director of Finance/CFO | 2020-03-26 |
| GENOCEA BIOSCIENCES, INC. | Director of Finance/CFO | 2018-03-22 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 2014-02-28 |
Odyssey Partners Ltd.
 Odyssey Partners Ltd. Investment ManagersFinance Odyssey Partners Ltd. (OPL) is an independent private equity investment firm located in London. Established in 2000 by Julian Fellerman and Richard Kleiner, OPL is the investment adviser of Avanti Capital Plc. (LSE: AVA), a UK-based private equity firm. | Corporate Officer/Principal | 2007-01-30 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Training of Jonathan Michael Poole
| London Business School | Masters Business Admin |
| University of Durham | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Odyssey Partners Ltd.
Odyssey Partners Ltd. Investment ManagersFinance Odyssey Partners Ltd. (OPL) is an independent private equity investment firm located in London. Established in 2000 by Julian Fellerman and Richard Kleiner, OPL is the investment adviser of Avanti Capital Plc. (LSE: AVA), a UK-based private equity firm. | Finance |
Avanti Capital PLC
 Avanti Capital PLC Financial ConglomeratesFinance Avanti Capital PLC engaged in investment management and ancillary services. The company was founded on February 17, 1997 and was headquartered in London, the United Kingdom. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Jonathan Michael Poole
